Safety and Tolerability of Antimalarial Therapies in Ugandan Children
Author Information
Author(s): Maiteki-Sebuguzi Catherine, Jagannathan Prasanna, Yau Vincent M, Clark Tamara D, Njama-Meya Denise, Nzarubara Bridget, Talisuna Ambrose O, Kamya Moses R, Rosenthal Philip J, Dorsey Grant, Staedke Sarah G
Primary Institution: Department of Medicine, Makerere University, Kampala, Uganda
Hypothesis
How do different combination antimalarial therapies affect safety and tolerability in Ugandan children with uncomplicated falciparum malaria?
Conclusion
The study confirms that AS+AQ and AL are safe and well-tolerated in Ugandan children, while AQ+SP is less well-tolerated, especially in younger children.
Supporting Evidence
- Participants treated with AQ+SP had a higher risk of anorexia and weakness compared to those treated with AL or AS+AQ.
- AL treatment was associated with a higher risk of elevated temperature compared to AS+AQ.
- Safety and tolerability outcomes were assessed at 14 and 42 days after treatment.
Takeaway
This study looked at how well different malaria treatments work for kids in Uganda. It found that some treatments are safer and easier for kids to handle than others.
Methodology
A longitudinal, single-blind, randomized clinical trial was conducted with children diagnosed with uncomplicated malaria, comparing three treatment regimens.
Potential Biases
Potential bias due to subjective interpretation of symptoms and the limited duration of active surveillance for adverse events.
Limitations
The study had a relatively small sample size and relied on subjective reports of symptoms, which may limit the findings.
Participant Demographics
Children aged 1 to 10 years from Kampala, Uganda, with a median age of 6.3 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 1.59 – 9.17 for anorexia; 95% CI 1.86 – 15.7 for weakness
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website